AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DIACEUTICS PLC

Director's Dealing Jun 18, 2021

7596_dirs_2021-06-18_8135c56a-0447-49e8-b00a-f402b2e76611.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3148C

Diaceutics PLC

18 June 2021

18 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase of Shares and PDMR Shareholding

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing announces that on 17 June 2021, Deborah Davis, the Chair of Diaceutics, purchased a total of 27,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares"). Of these, 20,000 were purchased at a price of 130 pence per Ordinary Share, and 7,000 at a price of 128 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 27,000 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde [email protected]
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Deborah Davis
2 Reason for notification
a. Position/Status Chair
b. Initial notification/

Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary shares of £0.002 each

ISIN:  GB00BJQTGV64
b. Nature of the transaction Purchase
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
130 p 20,000
128 p 7,000
d. Date of the transaction 17 June 2021
e. Place of the transaction AIM Market of the London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFSARTIDLIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.